NIH Funding Announcements

Syndicate content
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 34 min 1 sec ago

Quantitative Imaging Tools and Methods for Cancer Therapy Response Assessment (UG3/UH3 Clinical Trial Optional)

Wed, 11/29/2017 - 12:37
Funding Opportunity PAR-18-248 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages research project applications under the cooperative agreement (UG3/UH3) mechanism to address the development, optimization and validation of quantitative imaging (QI) software tools and methods for prediction and/or measurement of response to cancer therapies or for planning and validating radiation therapy treatment strategies in clinical trials.
Categories: NIH-Funding

Strengthening the HIV Pre-Exposure Prophylaxis (PrEP) Care Continuum through Behavioral, Social, and Implementation Science (R01 Clinical Trial Optional)

Wed, 11/29/2017 - 12:35
Funding Opportunity PA-18-281 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits behavioral, social, and implementation science research designed to (a) identify gaps in the HIV pre-exposure prophylaxis (PrEP) care continuum and associated determinants; (b) develop and test interventions to strengthen PrEP delivery, use, and outcomes; and (c) reduce racial/ethnic and age-related disparities in PrEP uptake and use.
Categories: NIH-Funding

Targeted Implementation Science to Achieve 90/90/90 Goals for HIV/AIDS Prevention and Treatment (R21 Clinical Trial Optional)

Wed, 11/29/2017 - 12:21
Funding Opportunity PA-18-280 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages implementation research projects designed in partnership with global and domestic service providers, to target the particular needs in the selected community, to achieve the 90/90/90 HIV prevention and treatment targets identified by HIV/AIDS global leadership. The targets for HIV testing are that 90% of all persons living with HIV know their status, for treatment initiation that 90% of those diagnosed receive timely and effective antiretroviral treatment (ART), and for optimal treatment and preventive benefit that 90% of those on treatment achieve sustained viral suppression.
Categories: NIH-Funding

Targeted Implementation Science to Achieve 90/90/90 Goals for HIV/AIDS Prevention and Treatment (R01 Clinical Trial Optional)

Wed, 11/29/2017 - 12:19
Funding Opportunity PA-18-279 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages implementation research projects designed in partnership with global and domestic service providers, to target the particular needs in the selected community, to achieve the 90/90/90 HIV prevention and treatment targets identified by HIV/AIDS global leadership. The targets for HIV testing are that 90% of all persons living with HIV know their status, for treatment initiation that 90% of those diagnosed receive timely and effective antiretroviral treatment (ART), and for optimal treatment and preventive benefit that 90% of those on treatment achieve sustained viral suppression.
Categories: NIH-Funding

NIA Intervention Testing Program (ITP) Announces Annual Call for Compounds to Test for Anti-Aging Activity in Mice

Wed, 11/29/2017 - 12:15
Notice NOT-AG-17-019 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Notice of Intent to Publish a Funding Opportunity Announcement for Mechanisms of Tolerance (R21/R33 - Clinical Trial Not Allowed)

Wed, 11/29/2017 - 12:10
Notice NOT-AA-17-017 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Notice of Intent to Publish a Funding Opportunity Announcement for Genetics of Tolerance (R01- Clinical Trial Not Allowed)

Wed, 11/29/2017 - 12:10
Notice NOT-AA-17-016 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Innovations in HIV Testing, Adherence, and Retention to Optimize HIV Care Continuum Outcomes (R01 Clinical Trial Optional)

Wed, 11/29/2017 - 12:06
Funding Opportunity PA-18-278 from the NIH Guide for Grants and Contracts. The health and preventive benefits of treatment for HIV/AIDS, regardless of CD4 count, are now unequivocal. In the United States and globally, ambitious goals have been targeted for HIV testing, adherence, and retention in care, to optimize HIV clinical outcomes and preventive benefit. Additional tools are needed to inform the gaps and strategies that are unique to particular populations, cities, regions, and countries. Applications appropriate for this FOA could include formative basic behavioral and social science to better understand a step in the care continuum and/or multiple steps in the HIV care continuum, initial development and pilot tests of innovative approaches for intervention, and intervention efficacy trials.
Categories: NIH-Funding

Innovations in HIV Testing, Adherence, and Retention to Optimize HIV Care Continuum Outcomes (R21 Clinical Trial Optional)

Wed, 11/29/2017 - 12:04
Funding Opportunity PA-18-277 from the NIH Guide for Grants and Contracts. The health and preventive benefits of treatment for HIV/AIDS, regardless of CD4 count, are now unequivocal. In the United States and globally, ambitious goals have been targeted for HIV testing, adherence, and retention in care, to optimize HIV clinical outcomes and preventive benefit. Additional tools are needed to inform the gaps and strategies that are unique to particular populations, cities, regions, and countries. Applications appropriate for this FOA could include formative basic behavioral and social science to better understand a step in the care continuum and/or multiple steps in the HIV care continuum, and initial development and pilot tests of innovative approaches for intervention.
Categories: NIH-Funding

Formative and Pilot Intervention Research for Prevention and Treatment of HIV/AIDS (R34 Clinical Trial Optional)

Wed, 11/29/2017 - 12:03
Funding Opportunity PA-18-276 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages formative research, intervention development, and pilot-testing of interventions. Primary scientific areas of focus include the feasibility, tolerability, acceptability and safety of novel or adapted interventions that target HIV prevention or treatment. For the purposes of this FOA, intervention is defined to include behavioral, social, or structural approaches, as well as combination biomedical and behavioral, social, or structural approaches that prevent acquisition and transmission of HIV infection, or improve clinical outcomes for persons who are HIV infected, or both.
Categories: NIH-Funding

Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)

Wed, 11/29/2017 - 12:01
Funding Opportunity PAR-18-190 from the NIH Guide for Grants and Contracts. This FOA encourages exploratory/developmental research applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying our current understanding of aging science. Applications appropriate to this FOA should be consistent with the scientific priorities outlined by the NIH Office of AIDS Research (OAR) as described in NOT-OD-15-137.
Categories: NIH-Funding

Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)

Wed, 11/29/2017 - 11:56
Funding Opportunity PAR-18-189 from the NIH Guide for Grants and Contracts. This FOA encourages applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying our current understanding of aging science. Applications appropriate to this FOA should be consistent with the scientific priorities outlined by the NIH Office of AIDS Research (OAR) as described in NOT-OD-15-137.
Categories: NIH-Funding

Notice of Correction to Application and Submission Information in PAR-18-341, "NCI Research Specialist (Laboratory-based Scientist) Award (R50)"

Wed, 11/29/2017 - 11:55
Notice NOT-CA-18-020 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Increased Knowledge and Innovative Strategies to Reduce HIV Incidence-iKnow Projects (R01 Clinical Trial Optional)

Wed, 11/29/2017 - 11:54
Funding Opportunity PAR-18-254 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to promote innovative research that addresses one or both of the following objectives: Devise optimal strategies to improve the identification of persons unaware of their HIV-1 infection and successfully link them to HIV testing, treatment, and prevention interventions. Develop and examine the feasibility and acceptability of novel integrated interventions of biomedical and behavioral strategies that substantially reduce the likelihood of onward HIV transmission in these populations.
Categories: NIH-Funding

Fast-Track Development of Medications to Treat Cannabis Use Disorders (UG3/UH3 Clinical Trial Optional)

Wed, 11/29/2017 - 11:52
Funding Opportunity PAR-18-221 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the discovery and development of medications to treat Cannabis Use Disorders (CUDs) using the UG3/UH3 mechanism. The objective is to advance medications toward the ultimate goal of obtaining FDA approval. Advances in understanding the cannabinoid systems and the effects of marijuana on the brain, coupled with the availability of both novel and marketed medications that may be efficacious to treat these disorders, offer unprecedented opportunities to develop safe and effective pharmacotherapies for CUDs.
Categories: NIH-Funding

NICHD Research Education Programs (R25 Clinical Trial Optional)

Wed, 11/29/2017 - 11:50
Funding Opportunity PAR-18-217 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NICHD R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs.
Categories: NIH-Funding

Notice of Correction to Application and Submission Information in PAR-18-342 "NCI Research Specialist (Core-based Scientist) Award (R50)"

Wed, 11/29/2017 - 11:46
Notice NOT-CA-18-021 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding